[go: up one dir, main page]

WO2001034198A3 - Oncolytic combinations for the treatment of cancer - Google Patents

Oncolytic combinations for the treatment of cancer Download PDF

Info

Publication number
WO2001034198A3
WO2001034198A3 PCT/US2000/030941 US0030941W WO0134198A3 WO 2001034198 A3 WO2001034198 A3 WO 2001034198A3 US 0030941 W US0030941 W US 0030941W WO 0134198 A3 WO0134198 A3 WO 0134198A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
oncolytic
combinations
oncolytic combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/030941
Other languages
French (fr)
Other versions
WO2001034198A2 (en
Inventor
Jason Scott Sawyer
Beverly Ann Teicher
Douglas Wade Beight
Edward C R Smith
William Thomas Mcmillen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU19166/01A priority Critical patent/AU1916601A/en
Publication of WO2001034198A2 publication Critical patent/WO2001034198A2/en
Publication of WO2001034198A3 publication Critical patent/WO2001034198A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Leukotriene (LTB4) antagonists enhance the effectiveness of 2',2'-difluoronucleoside anti-cancer agents.
PCT/US2000/030941 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer Ceased WO2001034198A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19166/01A AU1916601A (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16490099P 1999-11-11 1999-11-11
US60/164,900 1999-11-11

Publications (2)

Publication Number Publication Date
WO2001034198A2 WO2001034198A2 (en) 2001-05-17
WO2001034198A3 true WO2001034198A3 (en) 2002-02-14

Family

ID=22596581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030941 Ceased WO2001034198A2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Country Status (2)

Country Link
AU (1) AU1916601A (en)
WO (1) WO2001034198A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Cancer combination therapy
AU2001261832A1 (en) * 2000-05-09 2001-11-20 Creighton University Methods for inhibiting proliferation and inducing apoptosis in cancer cells
JP2004505047A (en) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド Cancer treatment by combined therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
DE10359828A1 (en) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP gemcitabine combination agents and their use as antitumor agents, in particular anti-metastatic agents
EP2080751A4 (en) 2006-10-12 2011-06-22 Inst Med Molecular Design Inc CARBOXYLIC ACID DERIVATIVE
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
KR20140099546A (en) 2012-01-10 2014-08-12 일라이 릴리 앤드 캄파니 Leukotriene b4 antagonist compound

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034135A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034137A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034134A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034133A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034135A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034137A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034134A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034133A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELIAS A.D.: "Future directions in lung cancer research and therapeutics.", HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA, (1997) 11/3 (519-527)., XP001024815 *

Also Published As

Publication number Publication date
WO2001034198A2 (en) 2001-05-17
AU1916601A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
HK1050132A1 (en) Oncolytic combinations for the treatment of cancer
ZA200201511B (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
MXPA02001497A (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents.
AU7834500A (en) Well treatment fluids comprising mixed aldehydes
HK1047283A1 (en) Tetrahydroquinoline derivatives having retinoid-like biological activity
ZA200006042B (en) Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections.
ZA993938B (en) Ziprasidone formulations.
ZA200202461B (en) Compounds for the treatment of ischemia.
DZ3165A1 (en) Food or pharmaceutical composition used to prevent or treat hyperoxaluria.
ZA993345B (en) Nefazodone dosage form.
TR199800436A3 (en) The use of primidine derivatives for cancer prevention.
MXPA02002086A (en) Metalcontaining compositions, preparations and uses.
ZA200108012B (en) Method of enhancing the efficacy of anti-tumor agents.
ZA200204325B (en) Area Denial.
WO2001034198A3 (en) Oncolytic combinations for the treatment of cancer
HK1043058A1 (en) Isophosphoramide mustard analogs and use thereof
WO2001034134A3 (en) Oncolytic combinations for the treatment of cancer
ZA200200309B (en) Fluid emulsified shortening composition.
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU1916501A (en) Oncolytic combinations for the treatment of cancer
ZA200205470B (en) Virus strains for the oncolytic treatment of cancer.
AU1917101A (en) Oncolytic combinations for the treatment of cancer
AU1595001A (en) Oncolytic combinations for the treatment of cancer
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200109120B (en) Use of Arylalkanoylpyridazines.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase